Toxicity of teriflunomide in aryl hydrocarbon receptor deficient mice

Biochemical Pharmacology
Chiara RedaelliTobias Volker Lanz

Abstract

The intracellular transcription factor aryl hydrocarbon receptor (AHR) is bound and activated by xenobiotics, thereby promoting their catabolism by inducing expression of cytochrome P450 oxidase (CYP) genes through binding xenobiotic response elements (XRE) in their promoter region. In addition, it is involved in several cellular pathways like cell proliferation, differentiation, regeneration, tumor invasiveness and immune responses. Several pharmaceutical compounds like benzimidazoles activate the AHR and induce their own metabolic degradation. Using newly generated XRE-reporter mice, which allow in vivo bioluminescence imaging of AHR activation, we show here that the AHR is activated in vivo by teriflunomide (TER), which has recently been approved for the treatment of multiple sclerosis. While we did not find any evidence that the AHR mediates the immunomodulatory effects of TER, AHR activation led to metabolism and detoxification of teriflunomide, most likely via CYP. Mice deficient for the AHR show higher blood levels of teriflunomide, suffer from enhanced thrombo- and leukopenia and elevated liver enzymes as well as from severe gastrointestinal ulcers and bleeding which are lethal after 8-11 days of treatment. Leukopenia, ...Continue Reading

References

Jun 11, 1992·Proceedings of the National Academy of Sciences of the United States of America·L Wu, J P Whitlock
Aug 15, 1994·Biochemical and Biophysical Research Communications·L AixP Galtier
May 9, 1997·The Journal of Biological Chemistry·N DzeletovicL Poellinger
Aug 29, 1998·Archives of Biochemistry and Biophysics·D PhelanM S Denison
Jun 21, 2002·Clinical Pharmacokinetics·Blaz Rozman
Apr 6, 2004·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Vivien ChanSusan E Tett
Jun 11, 2008·Critical Reviews in Eukaryotic Gene Expression·Timothy V BeischlagGary H Perdew
Oct 30, 2008·Annals of the Rheumatic Diseases·I González-AlvaroF Sánchez-Madrid
Feb 5, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Ryou FukushimaHiroshi Kitagawa
Feb 27, 2009·Congenital Anomalies·Ryou FukushimaHiroshi Kitagawa
Oct 20, 2010·PloS One·Edmond F O'DonnellSiva Kumar Kolluri
May 7, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·Qiang ShiWilliam F Salminen
Oct 14, 2011·The New England Journal of Medicine·Paul O'ConnorUNKNOWN TEMSO Trial Group
Jul 13, 2012·Arthritis Research & Therapy·Michael D WieseSusanna M Proudman
Dec 12, 2012·Drug Discovery Today·Erwan GuyotXavier Coumoul
May 21, 2013·Expert Opinion on Drug Metabolism & Toxicology·Michael D WieseCatherine O'Doherty
Apr 9, 2014·Cancer Immunology, Immunotherapy : CII·George C PrendergastAlexander J Muller
Jun 17, 2014·Nature·Alban BessedePaolo Puccetti
Jan 9, 2015·Nature Reviews. Cancer·Iain A MurrayGary H Perdew

❮ Previous
Next ❯

Citations

May 28, 2016·Neurology. Neuroimmunology and Neuroinflammation·Nadine KramannWolfgang Brück
Sep 24, 2020·Cellular and Molecular Life Sciences : CMLS·Jing-Ru LiuYing-Yong Zhao
Dec 4, 2020·International Journal of Molecular Sciences·Irina TerekhovaHoracio Pérez-Sánchez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.